MDG與 SNBL簽訂合作備忘錄，帶領台灣生技新藥產業打入世界盃 - MDG麥德凱

Honesty•Accuracy

Professionalism•Responsibility

Honesty•Accuracy

Professionalism•Responsibility

Honesty•Accuracy•Professionalism•Responsibility

Core Value

About
MDG

Medgaea Life Sciences is a third party laboratory that is certificated for OECD GLP, TFDA GLP, ISO 17025 and ISO 9001. Maily based on preclinical CRO, we provide total-soltion services to assist biotechnology industries successfully obtain the product certification and exploit internation market.

CRO

Needs Discuss
Quote and Ordar
Timetable Schedule
Report Launch
Case Closed

Services

With devoting to our core value 『Honesty•Accuracy•Professionalism•Responsibility』,

We have successfully assisted our customers to successfully obtain the product certification in FDA, CE, TFDA and NMPA.

Medical Devices

One of the first priority of medical devices R&D is their safety. The Biocompatibility test is mainly followed the ISO 10993 international standard.

Cell therapy and Regenerative medicine

We assist the safety, effectiveness tests during the R&D process of cell therapy product. All the tests are complied with GLP.

Pharmaceutical development

As the agent of SNBL in Taiwan, will help new drugs company to complete non-clinical trials in medium, large animals and primates in the research and development stage.

Agrochemical and Enviromental Agents

The agroculture products need to review their toxicological data in advance, and all the tests must be carried out in complies with GLP.

Chemical Substances

Providing the toxicological test information!
EPA acquired the test information as the core basis to evaluate the substance announcement.

Health Food/ Ingredients

Provide safety, efficacy and stability tests for food ingredients and health foods.

Registration

Provide registration services.

Pharmaceuticals

Provide batch examine for medicine release, including pyrogen, acute systemic toxicity and other tests.

Laboratory animals and Equipment

An agent and supplier based on research and development of animal experiments, providing import services for various disease model animals in research institutions.

2018年8月3日由財團法人資策會台日產業推動中心(TJIC)主辦之「台灣最新商務研討會」，麥德凱生科股份有限公司(MDG)與新日本科學株式會社(SNBL) 於東京簽訂合作協定。

(左) 麥德凱生科股份有限公司洪志駿總經理
(右)株式會社新日本科學福﨑好一郎副會長

(左起)麥德凱生科股份有限公司宮田定磨日本分社社長/經濟部工業局電資組呂正欽副組長/經濟部工業局楊志清副局長/總統府何美玥國策顧問/麥德凱生科股份有限公司洪志駿總經理/株式會社新日本科學福﨑好一郎副會長/經濟部曾文生政務次長/台北駐日經濟文化代表處周立組長/經濟部台日產業合作推動辦公室陳龍組長/株式會社新日本科學和泉博之本部長

SNBL新日本科學為日本最大的臨床前CRO企業，為生物製藥公司提供開發服務的領先業者

已有超過60年的歷史，專長服務項目在於中大型動物與靈長類試驗的臨床前CRO公司。支援醫療研究開發的所有步驟，加上充實的研究開發支援體制，以及超過2000多件生物醫藥品及再生醫療等製品等評估實績，於美國、亞洲擁有多數據點、提供全球性的醫藥品開發服務。

本次的合作協議的完成，將補足MDG在生技新藥委託研發的不足，並可藉由SNBL深厚的臨床前研究專長、全球性經驗及專業設施的組合優勢，帶領台灣生技新藥產業邁向國際化。